Literature DB >> 7571411

The influenza virus NS1 protein forms multimers in vitro and in vivo.

M E Nemeroff1, X Y Qian, R M Krug.   

Abstract

The NS1 protein of the influenza A virus inhibits both the nuclear export of mRNA and pre-mRNA splicing. Two functional domains, an RNA-binding domain and an effector domain, have been identified in this protein. Here we demonstrate that the NS1 protein exists as a dimer in vitro both in the absence of its RNA target and when it is bound to a specific RNA target, U6 snRNA. This indicates that it is most likely the dimer that binds to the RNA target. Mutational analysis indicated that the RNA-binding and dimerization domains are coincident. Multimerization also occurs in vivo, as assayed using the yeast two-hybrid system. In contrast to the situation in vitro, multimerization in vivo was mediated by not only the RNA-binding domain but also the effector domain. This suggests that multimerization in vivo involves a cellular protein cofactor that bridges more than one NS1 protein molecule together via their effector domains.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7571411     DOI: 10.1006/viro.1995.1499

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  Glycine 184 in nonstructural protein NS1 determines the virulence of influenza A virus strain PR8 without affecting the host interferon response.

Authors:  Sabine Steidle; Luis Martínez-Sobrido; Markus Mordstein; Stefan Lienenklaus; Adolfo García-Sastre; Peter Stäheli; Georg Kochs
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Eukaryotic translation initiation factor 4GI is a cellular target for NS1 protein, a translational activator of influenza virus.

Authors:  T Aragón; S de la Luna; I Novoa; L Carrasco; J Ortín; A Nieto
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

3.  The NS1 gene contributes to the virulence of H5N1 avian influenza viruses.

Authors:  Zejun Li; Yongping Jiang; Peirong Jiao; Aiqin Wang; Fengju Zhao; Guobin Tian; Xijun Wang; Kangzhen Yu; Zhigao Bu; Hualan Chen
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

4.  U6atac snRNA, the highly divergent counterpart of U6 snRNA, is the specific target that mediates inhibition of AT-AC splicing by the influenza virus NS1 protein.

Authors:  W Wang; R M Krug
Journal:  RNA       Date:  1998-01       Impact factor: 4.942

5.  Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein.

Authors:  W Yuan; R M Krug
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

6.  The R35 residue of the influenza A virus NS1 protein has minimal effects on nuclear localization but alters virus replication through disrupting protein dimerization.

Authors:  Erin N Lalime; Andrew Pekosz
Journal:  Virology       Date:  2014-05-05       Impact factor: 3.616

7.  Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3'-end processing machinery.

Authors:  Z Chen; Y Li; R M Krug
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

8.  The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target.

Authors:  Karen Y Twu; Diana L Noah; Ping Rao; Rei-Lin Kuo; Robert M Krug
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

9.  Functional replacement of the carboxy-terminal two-thirds of the influenza A virus NS1 protein with short heterologous dimerization domains.

Authors:  Xiuyan Wang; Christopher F Basler; Bryan R G Williams; Robert H Silverman; Peter Palese; Adolfo García-Sastre
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

10.  The RNA binding domain of influenza A virus NS1 protein affects secretion of tumor necrosis factor alpha, interleukin-6, and interferon in primary murine tracheal epithelial cells.

Authors:  Celeste M Newby; Leah Sabin; Andrew Pekosz
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.